JAZZ Q2 2017 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$11B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$394M+3.5% YoY

Gross Profit

$366M92.7% margin

Operating Income

$165M41.8% margin

Net Income

$106M26.8% margin

EPS (Diluted)

$1.72

QoQ Revenue Growth

+4.9%

Cash Flow

Operating Cash Flow

$135M

Free Cash Flow

$125M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$4.8B

Total Liabilities

$2.6B

Stockholders' Equity

$2.2B

Cash & Equivalents

$239M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$394M	$381M	+3.5%
Gross Profit	$366M	$357M	+2.4%
Operating Income	$165M	$169M	-2.2%
Net Income	$106M	$111M	-5.1%

Revenue Segments

Xyrem

$298M76%

Erwinaze And Erwinase

$49M13%

Defitelio

$30M8%

Other Products

$7M2%

Prialt

$6M1%

Geographic Segments

UNITED STATES

$357M90%

Europe

$27M7%

Other Countries

$10M3%